Preliminary analysis of another investigation targeting bladder cancer found a higher-than-anticipated rate of tumor downstaging, suggesting that intravesical administration of MV-NIS has clinical utility against bladder cancer and may act synergistically with checkpoint blockade therapies (132). The gene discussed is SLC5A5; the disease is urinary bladder cancer.